NCT04018222 (TOTAL FEEDBACK) is a clinical trial in System; Lupus Erythematosus, sponsored by Progentec Diagnostics, Inc..

Who is sponsoring NCT04018222?

NCT04018222 is sponsored by Progentec Diagnostics, Inc..

What condition does NCT04018222 study?

NCT04018222 studies System; Lupus Erythematosus, Lupus Erythematosus, SLE, Lupus Flare.

Is NCT04018222 still recruiting?

NCT04018222 is currently status unknown. Last updated 16 September 2020.

Last reviewed 2020-09-16 · How we verify

NCT04018222: TOTAL FEEDBACK

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Translation of a Diagnostic Test for Lupus Flare Prediction From Bench to Clinic

Status unknown Last updated 16 September 2020

What this trial tests

trial in System; Lupus Erythematosus in 60 participants. Status unknown.

Timeline

31 May 2019

Primary endpoint
31 December 2020

31 December 2020

Quick facts

Lead sponsor	Progentec Diagnostics, Inc.
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	60
Start date	31 May 2019
Primary completion	31 December 2020
Estimated completion	31 December 2020
Sites	3 locations across United States

Conditions studied

System; Lupus Erythematosus — all drugs for System; Lupus Erythematosus →
Lupus Erythematosus — all drugs for Lupus Erythematosus →
SLE — all drugs for SLE →
Lupus Flare — all drugs for Lupus Flare →

Sponsor

Progentec Diagnostics, Inc.

Who can join

18 and older, any sex, with System; Lupus Erythematosus or Lupus Erythematosus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is investigating the development of a diagnostic test intended to predict flares in patients with Systemic Lupus Erythematosus. Over a six-month period, the participant will donate blood samples for researchers to evaluate the types of proteins that are in their blood. During this time the participant will also visit a research physician to undergo a physical exam that will include an evaluation of the disease's level of activity. Questionnaires will be answered too, either via email, phone call, or a research app for android and iPhone devices. During this six-month period, if the participant experiences a lupus flare, they are strongly encouraged to visit the research physician to receive a complimentary medical evaluation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Progentec Diagnostics, Inc. trials

Trials by the same sponsor.

NCT04449653 — Mobile Study to Measure and Predict Lupus Disease Activity Using Digital Signals · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04018222 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Progentec Diagnostics, Inc.
Last refreshed: 16 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04018222.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing